Girolami A, Fabris F, Casonato A, Randi M L
Clin Lab Haematol. 1982;4(1):23-6. doi: 10.1111/j.1365-2257.1982.tb00055.x.
The effect of Sulphinpyrazone on the anticoagulant response to Warfarin was evaluated by a double-blind study in 11 patients with prosthetic heart valves. Six patients received Warfarin and Sulphinpyrazone and 5 Warfarin and placebo. Sulphinpyrazone potentiated the anticoagulant effect of Warfarin. Patients receiving Sulphinpyrazone needed about half the amount of Warfarin as compared to the control group. There were four bleeding episodes in the Sulphinpyrazone group and one episode in the control group. It was difficult to regulate the dose of Warfarin in patients also receiving Sulphinpyrazone.
通过对11例人工心脏瓣膜患者进行双盲研究，评估了磺吡酮对华法林抗凝反应的影响。6例患者接受华法林和磺吡酮治疗，5例患者接受华法林和安慰剂治疗。磺吡酮增强了华法林的抗凝作用。与对照组相比，接受磺吡酮治疗的患者所需华法林剂量约为一半。磺吡酮组有4次出血事件，对照组有1次出血事件。同时接受磺吡酮治疗的患者很难调整华法林的剂量。
